  The phase III BNT162b2 mRNA COVID-19 vaccine trial is based on a Bayesian
design and analysis, and the main evidence of vaccine efficacy is presented in
Bayesian statistics. Confusion and mistakes are produced in the presentation of
the Bayesian results. Some key statistics, such as Bayesian credible intervals,
are mislabeled and stated as confidence intervals. Posterior probabilities of
the vaccine efficacy are not reported as the main results. We illustrate the
main differences in the reporting of Bayesian analysis results for a clinical
trial and provide four recommendations. We argue that statistical evidence from
a Bayesian trial, when presented properly, is easier to interpret and directly
addresses the main clinical questions, thereby better supporting regulatory
decision making. We also recommend using abbreviation "BI" to represent
Bayesian credible intervals as a differentiation to "CI" which stands for
confidence interval.
